Moderna 2022 Priorities and Capital Allocation
In comparing .211 booster to 1273 at Day 29, superiority was met for
ancestral SARS-CoV-2 and all variants of concern
Geometric Mean Ratio
0
Ancestral
Iwith D614G
Beta
Delta
Omicron
2.74
1.28
T
1.68
1.75
1.33
Day 29
Day 181
Day 29
Day 181
Day 29
1.20
Day 181
Day 29
2.20 2.15
Day 181
•
•
The clinical endpoint to demonstrate
superiority was based on the
neutralizing antibody geometric
mean titer ratio (GMR); superiority
was considered met if the lower
bound of 95% CI of the GMR was >1
The GMR at Day 29 against:
-
Ancestral SARS-COV-2 was 1.28
(1.08, 1.51)
-
Beta was 1.33 (1.09, 1.61)
-
Delta was 1.75 (1.47, 2.10)
-
Omicron was 2.20 (1.74, 2.79)
.
At Day 181, superiority was met for
ancestral SARS-CoV-2, Beta and
Omicron variants; non-inferiority met
for Delta variant
Chalkias, Spyros et al. https://www.researchsquare.com/article/rs-1555201/v1
GMR, estimated by the ratio of the geometric least squares mean (GLSM) and the corresponding 2-sided 95% CI were used to assess the treatment difference. The GLSM and
Slide 20 corresponding 2-sided 95% CI for the antibody titers for each treatment group were estimated using a mixed effect model for repeated measures, adjusting for age groups and pre- moderna
booster titers. The GLSM, and the corresponding 95% CI results in log-transformed scale estimated from the model were back-transformed to obtain estimates in the original scaleView entire presentation